Contrast Media Injectors Market Booming Worldwide Report 2021-2028 | General Electric, Mallinckrodt, Guerbet SA, Bayer AG

Overview

Contrast media injectors inject contrast media or contrast agents into tissues to improve blood flow and perfusion. Prior to an MRI scan, MRI injectors are used to inject contrast media into the vascular system. Automated electromechanical injectors with reusable, disposable, or both syringes are commonly included in these applications. One MRI injector is referred to as a unit. Injectors for MRI are significantly more expensive than CT injectors.

By the end of 2027, the global contrast media injectors market is expected to be worth US$ 2,000.7 million and have a capacity of 49,381 units.

To Get more Business Statergies Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/3157

Drivers

Over the forecast period, the global contrast media injectors market is expected to rise due to an increase in the prevalence of CVDs (cardiovascular diseases). As per the American Heart Association's (AHA) 2018 report on heart disease and stroke figures, CHD (coronary heart disease) is the leading cause of CVD-related deaths in the United States, accounting for 43.8 percent of all deaths, and over 130 million people in the United States are estimated to have some kind of CVD by 2035.

Opportunities

Market players should foresee attractive growth prospects as the geriatric population grows. According to the World Health Organization, the proportion of the global population aged 60 and up is projected to rise from 12 percent to 22 percent by 2050.

Restraints

Air emboli development, which occurs from a massive air infusion that produces an air lock in the pulmonary artery, causes blood pressure to drop suddenly, accompanied by cardiovascular failure, is a severe problem encountered during contrast media injection. As a result, the global contrast media injectors market is projected to slow down.

Key Takeaways

The CT Injectors segment of the global contrast media injectors market was worth US$ 514.4 million in 2018, and is projected to develop at a CAGR of 6.0 percent to US$ 864.6 million by 2027. The increasing prevalence of chronic diseases is responsible for the segment's development.

In terms of sales, the hospitals segment dominated the global contrast media injectors market in 2018, contributing about 48.9% of the market, led by ambulatory surgical centers. During the forecast period, increasing healthcare infrastructure in developed countries is expected to fuel market growth.

To Get Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/3157

Market Trends

The market's major players are concentrating on developing immune medical devices for the cTACE treatment in adults with documented intermediate-stage hepatocellular carcinoma (HCC). The Ministry of Health & Family Welfare granted Guerbet certification in India for its novel traditional cTACE (Trans-Arterial Chemo-Embolization) mixing and injection method, Vectorio, in December 2019.

The market is now seeing an increase in mergers and acquisitions. In August 2019, Bracco Imaging purchased Syncona Ltd.’s Blue Earth Diagnostics, a molecular imaging firm headquartered in the U.K.

Competitive Landscape

Key companies contributing in the global contrast media injectors market are Bayer AG, Mallinckrodt, General Electric, Medtronic, Nemoto Kyorindo Co. Ltd., Ulrich GmbH & Co. KG, Guerbet SA, and Bracco Imaging S.p.A.

Key Developments

Key market players are concentrating on the acceptance and sale of new products in order to extend their product range. Guerbet received approval in Denmark in November 2019 for a new indication for Lipiodol Ultra Fluid: chemoembolization of tumors in adults with known intermediate-stage hepatocellular carcinoma.

Partnership initiatives are now being pursued by key market leaders in order to broaden their product range. Bracco Imaging S.p.A., joined with R.A.W. S.r.l., an Italian organization focusing on Augmented Reality Guidance technology in Interventional Oncology procedures, on March 3, 2018, to extend its suite of Interventional Oncology solutions.

Get Discount On The Purchase Of This Report @: https://www.coherentmarketinsights.com/promo/buynow/3157

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Coherent Market Insights :

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.